JP2005515964A5 - - Google Patents

Download PDF

Info

Publication number
JP2005515964A5
JP2005515964A5 JP2003508362A JP2003508362A JP2005515964A5 JP 2005515964 A5 JP2005515964 A5 JP 2005515964A5 JP 2003508362 A JP2003508362 A JP 2003508362A JP 2003508362 A JP2003508362 A JP 2003508362A JP 2005515964 A5 JP2005515964 A5 JP 2005515964A5
Authority
JP
Japan
Prior art keywords
enantiomer
prodrug
isomer
salt
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003508362A
Other languages
English (en)
Other versions
JP2005515964A (ja
Filing date
Publication date
Priority claimed from US09/892,981 external-priority patent/US20030027804A1/en
Application filed filed Critical
Publication of JP2005515964A publication Critical patent/JP2005515964A/ja
Publication of JP2005515964A5 publication Critical patent/JP2005515964A5/ja
Pending legal-status Critical Current

Links

Claims (12)

  1. それを必要とする雌性哺乳動物、好ましくはヒトにおいて、更年期障害が進行する危険性を治療し、予防し又は軽減させる組み合わせ医薬を製造するためのメチルテストステロン及び少なくとも1つの医薬的に許容可能なステロイドの使用であって、該組み合わせ医薬は:約0.2mg〜約50.0mgのメチルテストステロン又はそのエナンチオマー、アイソマー、プロドラッグ若しくは塩を経口投与量単位による投与のために;約0.1g〜約100.0mgのエストラジオール又はそのエナンチオマー、アイソマー、プロドラッグ若しくは塩を非経口投与量単位による投与のために含む、前記使用。
  2. メチルテストステロンを、錠剤、カプセル、カシェ剤、トローチ剤、調合散剤、顆粒剤、液剤、懸濁剤、エマルジョン又はリキッドの形態で投与する、請求項1に記載の使用。
  3. エストラジオール又はそのエナンチオマー、アイソマー、プロドラッグ若しくは塩を経皮投与する、請求項1に記載の使用。
  4. エストラジオール又はそのエナンチオマー、アイソマー、プロドラッグ若しくは塩を水性アルコールジェルの形態で投与する、請求項3に記載の使用。
  5. 水性アルコールジェルが、低級アルコール及び増粘剤のうちの少なくとも1つを更に含む、請求項4に記載の使用。
  6. 低級アルコールが、エタノール、2−プロパノール及びそれらの混合物から成る群より選択される、請求項5に記載の使用。
  7. 増粘剤がポリアクリル酸である、請求項5に記載の使用。
  8. エストラジオール又はそのエナンチオマー、アイソマー、プロドラッグ若しくは塩が経皮ジェル製剤として投与され、該製剤が、製剤の重量に対して:
    (a) 約0.06〜約10.0重量%のエストラジオール又はそのエナンチオマー、アイソマー、プロドラッグ若しくは塩;
    (b) 約0.1〜約5.0重量%のポリアクリル酸;
    (c) 約0.1〜約5.0重量%のトリエタノールアミン;
    (d) 約30.0〜約98.0重量%のエタノール;及び
    (e) 製剤を100重量%にするのに十分な量の水、
    を含む、請求項1に記載の使用。
  9. メチルテストステロン又はそのエナンチオマー、アイソマー、プロドラッグ若しくは塩及びエストラジオール又はそのエナンチオマー、アイソマー、プロドラッグ若しくは塩をキットの別成分としてそれぞれ提供する、請求項1に記載の使用。
  10. 哺乳動物がヒトである、請求項1に記載の使用。
  11. メチルテストステロン又はそのエナンチオマー、アイソマー、プロドラッグ若しくは塩及びエストラジオール又はそのエナンチオマー、アイソマー、プロドラッグ若しくは塩を連続的に投与する、請求項1に記載の使用。
  12. メチルテストステロン又はそのエナンチオマー、アイソマー、プロドラッグ若しくは塩及びエストラジオール又はそのエナンチオマー、アイソマー、プロドラッグ若しくは塩を実質的に同時に投与する、請求項1に記載の使用。
JP2003508362A 2001-06-27 2002-06-26 ホルモン欠乏症を治療するための治療用組成物 Pending JP2005515964A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/892,981 US20030027804A1 (en) 2001-06-27 2001-06-27 Therapeutic combinations for the treatment of hormone deficiencies
PCT/US2002/020141 WO2003002123A2 (en) 2001-06-27 2002-06-26 Therapeutic combinations for the treatment of hormone deficiencies

Publications (2)

Publication Number Publication Date
JP2005515964A JP2005515964A (ja) 2005-06-02
JP2005515964A5 true JP2005515964A5 (ja) 2006-01-05

Family

ID=25400826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003508362A Pending JP2005515964A (ja) 2001-06-27 2002-06-26 ホルモン欠乏症を治療するための治療用組成物

Country Status (5)

Country Link
US (1) US20030027804A1 (ja)
EP (1) EP1404343A4 (ja)
JP (1) JP2005515964A (ja)
CA (1) CA2451725C (ja)
WO (1) WO2003002123A2 (ja)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
IL163981A0 (en) * 2002-03-15 2005-12-18 Unimed Pharmaceuticals Inc Androgen pharmaceutical composition and method fortreating depression
MY139721A (en) 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050222106A1 (en) * 2004-04-01 2005-10-06 Stefan Bracht Drospirenone-containing preparations for transdermal use
PT1750766E (pt) 2004-05-11 2013-09-30 Emotional Brain Bv Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina
KR20070073964A (ko) * 2004-11-01 2007-07-10 앙도르쉐르슈 인코포레이티드 피부 노화 치료용 또는 피부 노화의 획득 가능성감소용으로서의 안드로겐의 용도
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
US20070154533A1 (en) * 2005-04-13 2007-07-05 Dudley Robert E Method of increasing testosterone and related steriod concentrations in women
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
RS52671B (en) 2005-10-12 2013-06-28 Unimed Pharmaceuticals Llc IMPROVED TESTOSTERON GEL AND USE PROCEDURE
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
US20070254036A1 (en) * 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2044943A1 (en) * 2007-10-04 2009-04-08 Solvay Pharmaceuticals, Inc. Pharmaceutical compositions comprising esterified estrogens and methyltestosterone and method of using the same
US20090285893A1 (en) * 2008-05-19 2009-11-19 The Procter & Gamble Company Treatment of heart failure in women
GB2482868A (en) * 2010-08-16 2012-02-22 Franciscus Wilhelmus Henricus Maria Merkus A testosterone liquid spray formulation for oromucosal administration
US9642862B2 (en) 2010-11-18 2017-05-09 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
AU2012256501B2 (en) 2011-05-13 2017-04-06 Eb Ip Hybritabs B.V. Drug delivery system
US9855281B2 (en) * 2013-11-20 2018-01-02 Scott Freeman Consultant, Llc Libido-enhancing therapeutic and use
US11439668B2 (en) 2014-05-23 2022-09-13 JangoBio, LLC Methods to differentiate stem cells into hormone-producing cells
US11253549B2 (en) * 2014-05-23 2022-02-22 JangoBio, LLC Methods to rebalance the hypothalamic-pituitary-gonadal axis
US20180207177A1 (en) * 2017-01-23 2018-07-26 Government Of The United States As Represented By The Secretary Of The Air Force TREATMENT OF TRIPLE NEGATIVE BREAST CANCER UTILIZING ANDROST-5-ENE-3b,17b-DIOL (b-AED), ANDROST-5-ENE-3b,7b,17b-TRIOL (b-AET) AND ESTRADIOL (E2)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8301550A (nl) * 1983-05-03 1984-12-03 Gist Brocades Nv Imidazolethanol esters.
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5639743A (en) * 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
ES2423899T3 (es) * 2000-08-30 2013-09-25 Unimed Pharmaceuticals, Llc Método para aumentar las concentraciones de testosterona y esteroides relacionados en las mujeres

Similar Documents

Publication Publication Date Title
JP2005515964A5 (ja)
RU2404750C2 (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
JP2023002662A5 (ja)
US8512751B2 (en) Pharmaceutical compositions for sleep disorders
JP2005537268A5 (ja)
HRP20161233T1 (hr) Neurozaštita u demijelinizirajućim bolestima
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
JP2005509662A5 (ja)
JP2002532392A5 (ja)
CN101073563B (zh) 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片
JP2005515966A5 (ja)
JP2009525343A5 (ja)
JP2006503850A5 (ja)
JP2013507415A5 (ja)
JP2015524444A5 (ja)
JP2009502951A5 (ja)
JP2019515884A5 (ja)
JP2008534592A5 (ja)
JP2019515908A5 (ja)
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
JP2005528430A5 (ja)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JP2019507786A5 (ja)
JP2002534477A5 (ja)